COMP <GO>
IMVT vs CGON // OPERATING MARGIN
Immunovant Inc. (NASDAQ) VS. CG Oncology Inc. (NASDAQ) • 15-METRIC TALLY: IMVT 2
— CGON 7
▲ OPERATING MARGIN LEADER: CGON
LAST: $29.04 (+2.22%) • MKT CAP: $5.87B
operating-margins
-36.00%
LAST: $64.06 (+3.39%) • MKT CAP: $5.49B
operating-margins
-12.10%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (IMVT VS. CGON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | IMVT | CGON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -20.80% | -14.20 | CGON | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -6.65% | -2.35% | -4.30 | CGON | /fcf-yield <GO> |
| Operating Margin ACTIVE | -36.00% | -12.10% | -23.90 | CGON | /operating-margins <GO> |
| Net Profit Margin | -29.50% | -10.20% | -19.30 | CGON | /net-margins <GO> |
| Revenue Growth (YoY) | 9.90% | 8.80% | +1.10 | IMVT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 26.00 | 0.00 | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 5/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 36.4 | 41.5 | -5.10 | CGON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.98 | 1.07 | -0.09 | CGON | /macro-sensitivity <GO> |
| Forward P/E Multiple | 36.0x | 20.0x | +16.00 | CGON | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.87B | $5.49B | $376.0M | IMVT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | IMVT REV | CGON REV | IMVT GROSS % | CGON GROSS % | IMVT FCF | CGON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.67B | $534.2M | — | — | -$407.3M | -$132.5M |
| FY 2024 | $1.37B | $321.1M | — | — | -$376.6M | -$78.9M |
| FY 2023 | $856.8M | $155.3M | — | — | -$214.2M | -$45.7M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
IMVT // BETA 0.98
CGON // BETA 1.07